| Similar Articles |
|---|
 |
The Motley Fool
January 28, 2008
Brian Lawler |
A Wing and a Prayer for Amgen Amgen announces data from its top pipeline drug candidate. Investors, take note.   |
The Motley Fool
August 19, 2009
Brian Orelli |
Them's the Breaks for Lilly The drugmaker cuts its losses after a disappointing trial on an osteoporosis drug. |
The Motley Fool
April 21, 2011
Luke Timmerman |
Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis. |
The Motley Fool
June 2, 2010
Brian Orelli |
Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market. |
The Motley Fool
February 26, 2010
Brian Orelli |
Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market. |
The Motley Fool
February 9, 2010
Brian Orelli |
Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status. |
The Motley Fool
November 19, 2010
Brian Orelli |
One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
The Motley Fool
October 26, 2010
Brian Orelli |
Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth. |
The Motley Fool
October 21, 2004
W.D. Crotty |
One Value-Priced Biotech Giant Amgen is a growing cash machine selling at the market's multiple to earnings. |
The Motley Fool
February 9, 2011
Luke Timmerman |
Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"? |
The Motley Fool
September 17, 2008
Brian Orelli |
Will Denosumab Strengthen Amgen's Bones? Recently passing its phase 3 trial will help get denosumab on the market. But two big questions remain: how well it worked, and whether anyone will buy it, given the drug's plentiful rivals. |
BusinessWeek
May 15, 2006
Arlene Weintraub |
Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors. |
The Motley Fool
October 20, 2005
Brian Gorman |
Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
October 19, 2009
Brian Orelli |
Still Waiting for Its Blockbuster Amgen announces a Food and Drug Administration delay for its long-awaited osteoporosis drug, Prolia, its treatment for postmenopausal osteoporosis. |
The Motley Fool
July 12, 2004
Ben McClure |
Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good. |
The Motley Fool
July 30, 2010
Brian Orelli |
On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually. |
BusinessWeek
June 4, 2007
Gene G. Marcial |
Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled. |
The Motley Fool
July 8, 2009
Brian Orelli |
Amgen Closes In on a Home Run Amgen already had a ball flying high above the outfield in its osteoporosis treatment, denosumab, but yesterday's clinical trial results were the wind that could push it out of the park. |
The Motley Fool
September 20, 2007
Billy Fisher |
More Options for Healthy Bones? Novartis and Wyeth might be able to offer alternative treatments for osteoporosis, but the companies have a tough road ahead in this market. |
BusinessWeek
January 14, 2010
Rob Waters |
Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology. |
The Motley Fool
May 13, 2005
Karl Thiel |
Boning Up on New Drugs Are new osteoporosis therapies compelling investments, or is the field too crowded? |
BusinessWeek
August 13, 2009
Arlene Weintraub |
Amgen's Bone-Loss Drug Faces Marketing Hurdles Amgen is likely to receive FDA approval for denosumab, its new biologic bone-loss drug, but it may be a hard sell against cheaper generics. |
The Motley Fool
October 22, 2009
Brian Orelli |
Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
October 24, 2008
Brian Orelli |
Amgen's Back Shares of Amgen are up 40% from their lows in March. And for good reason. |
The Motley Fool
October 29, 2007
Brian Lawler |
Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader. |
The Motley Fool
April 25, 2011
Brian Orelli |
Dividend Investors Rejoice! Or Not. Amgen establishes a dividend, investors yawn. |
Pharmaceutical Executive
October 1, 2008
Joanna Breitstein |
The D-Mab Men Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug for the multi-billion dollar osteoporosis market |
The Motley Fool
March 11, 2010
Brian Orelli |
FDA Still Has a Bone to Pick With These Drugmakers Osteoporosis drugs remain under the microscope. |
The Motley Fool
May 27, 2009
Brian Orelli |
A Partnership of the Heart Amgen, the large biotech company, exercises its right to license Cytokinetic's cardiac contractility program, including heart failure drug CK-1827452. |
The Motley Fool
July 28, 2008
Brian Lawler |
Amgen's Bone-Building Boost The drugmaker gets good news about a top pipeline compound. |
The Motley Fool
April 24, 2007
Brian Lawler |
Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices. |
The Motley Fool
January 7, 2010
Brian Orelli |
Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA. |
The Motley Fool
December 26, 2006
Brian Lawler |
2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year. |
BusinessWeek
June 21, 2004
Catherine Arnst |
Guard Your Bones Osteoporosis is one of the biggest health risks facing older women. What can be done to help prevent this disease? |
The Motley Fool
October 25, 2011
Brian Orelli |
Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway. |
The Motley Fool
January 26, 2010
Brian Orelli |
Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010. |
The Motley Fool
December 10, 2010
Brian Orelli |
Something Is Better Than Nothing, I Guess Novartis' Zometa fails a critical clinical trial. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends. |
The Motley Fool
August 14, 2009
Brian Orelli |
Amgen Close to Scoring Big Amgen gets good-enough results from a FDA panel. |
The Motley Fool
July 21, 2005
Tom Taulli |
Amgen One-Ups Genentech New Medicare regulations look to be harmless, and as a result, Amgen is off to the races. Still, investing in biotech is always dicey. |
The Motley Fool
September 5, 2007
Billy Fisher |
Lilly's Pipeline Continues to Produce Another schizophrenia drug from the company shows promise in a clinical trial, prompting the company to plan additional trials. This is the latest good news in what has been a good year for Lilly. |
The Motley Fool
November 9, 2006
Karl Thiel |
The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note. |
The Motley Fool
August 11, 2010
Brian Orelli |
Amgen Comes Up a Little Short Amgen's drug Vectibix improves survival, but not by enough. |
The Motley Fool
December 22, 2009
Brian Orelli |
2009 Biotech Cheers and Jeers Lessons from biotech's 2009 surprises. Will 2010 be just as exciting? Considering that it's biotech, I'd have to say "yes." |
The Motley Fool
May 18, 2011
Brian Orelli |
More Data, Same Controversy Will Amgen's Xgeva be used to delay bone metastasis? |
The Motley Fool
October 24, 2006
Brian Lawler |
Amgen's Ho-Hum Quarter With all the money flowing into its coffers, the biotech has no excuse not to start paying a dividend. |
The Motley Fool
April 28, 2008
Brian Lawler |
Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings. |
